ArticleFrontiers in oncology2020
Microbiome Related Cytotoxically Active CD8+ TIL Are Inversely Associated With Lung Cancer Development.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Microbiome and Response to Therapy in Triple Negative Breast Cancer: A Systematic Review.Oncology research · 2026Pooled it
- Intratumoral microbiota in the growth of CRC and lung cancer: Comprehensive insights from etiology to therapy.iScience · 2026Review
- Analysis of intratumoural bacteria: Opportunities and challenges for cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Deciphering the intratumor microbiota in malignant gastrointestinal tumors: multifaceted interplay and clinical implications.Cell communication and signaling : CCS · 2026Review
- Intratumoral Microbiota in Lung Cancer: Emerging Roles in TME Modulation and Immunotherapy Response.International journal of molecular sciences · 2025Review
- Characteristics of gut and lung microbiota in patients with lung masses and their relationship with clinical features.BMC microbiology · 2025Article
- A Perspective on Lung Cancer and Lung Microbiome: Insight on Immunity.Immunity, inflammation and disease · 2025Review
- Tumor microenvironment signatures enhances lung adenocarcinoma prognosis prediction: Implication of intratumoral microbiota.Microbial cell (Graz, Austria) · 2025Article
- Implications of intratumoral microbiota in tumor metastasis: a special perspective of microorganisms in tumorigenesis and clinical therapeutics.Frontiers in immunology · 2025Review
- Integrative multi-omics analysis of the microbiome and metabolome in bronchoalveolar lavage fluid from patients with early-stage lung cancer.Frontiers in cellular and infection microbiology · 2025Article
- Respiratory microbiome-host interaction on lung carcinogenesis, immunity, and immunotherapy.Frontiers in immunology · 2025Review
- Intratumoral microbiota: synergistic reshaping of lung cancer microenvironment via inflammation and immunity.Frontiers in immunology · 2025Review
- Toxicity assessment of Cucurbita pepo cv Dayangua and its effects on gut microbiota in mice.BMC complementary medicine and therapies · 2024Article
- Unique Changes in the Lung Microbiome following the Development of Chronic Lung Allograft Dysfunction.Microorganisms · 2024Article
- Intratumoural microbiota: a new frontier in cancer development and therapy.Signal transduction and targeted therapy · 2024Review
- Symbiotic microbial communities in various locations of the lung cancer respiratory tract along with potential host immunological processes affected.Frontiers in cellular and infection microbiology · 2024Review
- Microbiome and cancer: from mechanistic implications in disease progression and treatment to development of novel antitumoral strategies.Frontiers in immunology · 2024Review
- The Role of Respiratory Microbiota in Lung Cancer.International journal of biological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the most common cancer type around the world. Although major advances in cancer therapy, lung cancer has been the largest proportion of all cancer-related deaths. The respiratory tract contains many types of bacteria and a distinct lung microbiome in lung cancer patients was described in many studies. The specific roles of these lung microorganisms in lung cancer progression remain unclear. In this study, we evaluated the effect of inhalation of bronchoalveolar fluid (BAL) in the lung cancer cell growth. The microbiome-based immune and carcinogenesis was examined in tumor-bearing mouse model. We found that inhalation of BAL collected from non-small cell lung cancer (NSCLC) patients altered the lung microbiota and inhibited tumor cell growth. The inhibitory effect was due to the infiltration of CD3 and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.